NC-NOVAQUEST-CAPITAL
20.5.2021 12:32:11 CEST | Business Wire | Press release
Argenta Limited (“Argenta”), the only global contract research organization (CRO) and contract development and manufacturing organization (CDMO) specializing in animal health, and NovaQuest Capital Management (“NovaQuest”) announced today a $30 million product financing agreement for the development of several innovative veterinary pharmaceuticals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005132/en/
The collaboration leverages NovaQuest’s capital and expertise, and Argenta’s knowledge and know-how in research and development activities that advance animal health.
“The capital investment from NovaQuest accelerates Argenta’s strategy of providing innovative solutions and Molecule to Market services through global partnerships. We are delighted by the collaboration with NovaQuest and we look forward to strengthening our partnership through additional programs in the future,” said Ben Russell, CEO of Argenta.
Argenta will conduct the R&D activities from its locations in the United States and New Zealand and will use proprietary drug delivery technologies to develop what are expected to be the next generation of veterinary pharmaceutical products. Argenta and NovaQuest will look for commercialization partners as the project progresses.
“This is an historic milestone for Argenta and instrumental in advancing our commitment to deliver innovation to the animal health industry. I am excited to leverage our product development expertise, IP and technology to accelerate some of the many options available,” commented Edward McGruder, Global head of Research, Development and Innovation at Argenta.
For NovaQuest, a premier biopharma and life sciences investment firm with extensive experience in human health product financing, this represents their first expansion into a collaboration of this nature within the animal health industry.
“We are excited to enter into this collaboration with Argenta, a trusted global leader in the animal health industry. With this investment we expand NovaQuest’s commitment to funding innovation in animal health across a wide range of companies and products,” said Jonathan Tunnicliffe, Chief Investment Officer of NovaQuest.
“NovaQuest’s commitment to bringing innovation to the animal health industry, combined with Argenta’s unparalleled end-to-end development capabilities and expertise make this a truly exciting collaboration,” said Brian Axe, Managing Director at NovaQuest .
Both companies are eager to start this product development journey to help accelerate innovation in the animal health industry.
Wyrick Robbins Yates & Ponton LLP acted as legal counsel to NovaQuest.
About NovaQuest
Founded by a team of accomplished industry professionals who began working together in 2000, NovaQuest Capital Management is a premier biopharma and life sciences investment firm. NovaQuest pioneered a Product Finance solution for the industry, providing at-risk, nondilutive funding that enables partner companies to advance pivotal clinical trials, launch new brands, license products, and acquire accretive products or companies. NovaQuest has invested in scores of biopharmaceutical assets across therapeutic areas with a clinical success rate higher than the industry average. Currently managing more than $2.2 billion in capital, NovaQuest is actively investing from the $1.2 billion Pharma Opportunities Fund V, evaluating global opportunities with financing needs that range from $30-100 million. Leveraging the core platform, NovaQuest is expanding its strategy to bring much needed capital to the animal health industry. NovaQuest is actively evaluating and investing in opportunities across animal segments and geographies. For more information, please visit www.novaquest.com
About Argenta
Argenta is the only combined global contract research organization (CRO) and contract development and manufacturing organization (CDMO) dedicated to animal health. Founded in 2006 in New Zealand, Argenta’s talented, diverse and committed employees work on a daily basis to deliver excellence in animal health to customers around the world. With research and GMP manufacturing operations in New Zealand, the United States and the United Kingdom, Argenta operates ‘from Molecule to Market’ in partnership with its customers to support their R&D, regulatory, clinical research and manufacturing needs along the veterinary product development journey. For more information about Argenta, please visit www.argentaglobal.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005132/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom